Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Rapid diagnosis of resistance-conferring mutations to antibiotics used for the treatment of tuberculosis (TB) is critical for patient care and public health control efforts. Prior guidelines included the use of fluoroquinolones (FQs) for the treatment of drug-resistant TB, including multidrug-resistant TB, pre-extensively drug-resistant TB, and extensively drug-resistant TB. More recently, a short-course regimen for antibiotic-susceptible TB was introduced, which includes the use of a FQ, a drug class that diagnostic algorithms in the United States (US) typically do not test for if all first-line agents are susceptible. However, FQ mono-resistance has been documented by previous studies, and for this reason, we tested 319 archived complex (MTBC) strains spanning a 14-year period of time using the Xpert MTB/XDR assay. Resistance to FQs was detected in 4.4% (14/319) of the isolates tested, with mutations predominating in the region (13/14; 92.9%). A single isolate (1/14; 7.1%) was found to have a mutation. A broth microdilution assay demonstrated the minimum inhibitory concentrations for resistant strains that ranged from 0.5 µg/mL to 8.0 µg/mL. Importantly, three strains were FQ mono-resistant and would have been completely missed by standard testing algorithms. Although currently unavailable in the US, the GeneXpert XDR assay has the potential to fill the significant diagnostic gap in susceptibility testing of MTBC resistance to FQs and support the use of the currently recommended short-course regimen.IMPORTANCE This study provides insight into the need for additional rapid testing for the detection of drug resistance (specifically to fluoroquinolones) in tuberculosis (TB) cases in the United States (US). The current regimens for TB treatment rely on knowing resistance patterns to optimize treatment, and missed resistance could have a negative impact on the health of the patient, as well as contribute to increased drug-resistance mutations in new TB cases. There are currently limited platforms for expanded rapid drug resistance testing for TB cases in the US, and this study looks at past TB cases that had drug resistance missed by routine testing.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1128/jcm.00643-25 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identifying meaningful drug response biomarkers from public pharmacogenomic datasets with biologically informed interpretable neural networks.
Comput Biol Chem
September 2025
Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macao Special Administrative Region of China. Electronic address:
With the advancements of next-generation sequencing, publicly available pharmacogenomic datasets from cancer cell lines provide a handle for developing predictive models of drug responses and identifying associated biomarkers. However, many currently available predictive models are often just used as black boxes, lacking meaningful biological interpretations. In this study, we made use of open-source drug response data from cancer cell lines, in conjunction with KEGG pathway information, to develop sparse neural networks, K-net, enabling the prediction of drug response in EGFR signaling pathways and the identification of key biomarkers.
View Article and Find Full Text PDFDeepMobilome: predicting mobile genetic elements using sequencing reads of microbiomes.
Brief Bioinform
September 2025
Department of Computer Science, Hanyang University, 222 Wangsimni-ro, Seoul 04763, Republic of Korea.
Motivation: Mobile genetic elements (MGEs) play an important role in facilitating the acquisition of antibiotic resistance genes (ARGs) within microbial communities, significantly impacting the evolution of antibiotic resistance. Understanding the mechanism and trajectory of ARG acquisition requires a comprehensive analysis of the ARG-carrying mobilome-a collective set of MGEs carrying ARGs. However, identifying the mobilome within complex microbiomes poses considerable challenges.
View Article and Find Full Text PDFTopoisomerase II inhibitors in oncology: an updated patent review (2016-present).
Expert Opin Ther Pat
September 2025
Dipartimento di Scienze per la Qualità della Vita, Alma Mater Studiorum - Università di Bologna, Rimini, Italy.
Introduction: Topoisomerase (topo) II inhibitors continue to represent a promising approach in anticancer therapy, although their clinical application is hampered by drug resistance and dose limiting toxicities.
Area Covered: We performed a critical analysis of patent literature from January 2016 to January 2025 on topo II inhibitors in oncology using the online databases Espacenet, Wipo, and Google patent.
Expert Opinion: Substantial progress in the development of novel topo II inhibitors through synthetic chemistry, natural product isolation, molecular modification, and in silico screening was recorded.
Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus.
Drug Deliv Transl Res
September 2025
Department of Pharmacy, Birla Institute of Technology and Science, Pilani, Pilani Campus, Vidya Vihar, Pilani, Rajasthan, 333031, India.
Diabetes is a metabolic disorder of increasing global concern. Characterized by constantly elevated levels of glucose, severe β-cell dysfunction, and insulin resistance, it is the cause of a major burden on patients if not managed with therapeutic and lifestyle changes. The human body is slowly developing tolerance to many marketed antidiabetic drugs and the quest for the discovery of newer molecules continues.
View Article and Find Full Text PDFMulticellular tumor-stromal interactions recapitulate aspects of therapeutic response and human oncogenic signaling in a 3D disease model for H3K27M-altered DIPG.
Oncogene
September 2025
Division of Neurosurgery, Children's Hospital Los Angeles, Los Angeles, CA, USA.
It has become evident from decades of clinical trials that multimodal therapeutic approaches with focus on cell intrinsic and microenvironmental cues are needed to improve understanding and treat the rare, inoperable, and ultimately fatal diffuse intrinsic pontine glioma (DIPG), now categorized as a diffuse midline glioma. In this study we report the development and characterization of an in vitro system utilizing 3D Tumor Tissue Analogs (TTA), designed to replicate the intricate DIPG microenvironment. The innate ability of fluorescently labeled human brain endothelial cells, microglia, and patient-derived DIPG cell lines to self-assemble has been exploited to generate multicellular 3D TTAs that mimic tissue-like microstructures, enabling an in- depth exploration of the spatio-temporal dynamics between neoplastic and stromal cells.
View Article and Find Full Text PDF